A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
With the in-depth study of tumor immune microenvironment, immune checkpoint inhibitors represented by PD-1/PD-L1 inhibitors have achieved promising results in tumor treatment. However, the treatment response rate is low with immunotherapy alone. Integrative therapy is the development trend of tumor therapy. The combined treatment strategies of PD-1/PD-L1 inhibitors with chemotherapy, radiotherapy, TKI, antiangiogenic drugs, etc. are being actively explored. This paper reviews the mechanism anddoi:10.3971/j.issn.1000-8578.2020.19.1400 doaj:2c56c9190e07454fbb402089514051da fatcat:sudkmiqgarag7k7754hfygf22m